Dana-Farber Cancer Institute boasts an impressive history of key discoveries about the immune system. Their powerhouse investigators have been on the frontlines. Dana-Farber’s research revealed that a protein known as PD-L1 is expressed on normal and cancer cells, enabling cancers to evade the immune response, and that blocking PD-L1 and a related protein, PD-1, could unleash the immune attack on tumor cells. PICI scientists at Dana-Farber are leaders in immunology and contribute greatly to our research agenda. Elizabeth A. Mittendorf, MD, PhD | Co-Director F. Stephen Hodi, MD | Co-Director Kai W. Wucherpfennig, MD, PhD | Co-Director All Investigators Related Press Release PICI, JDRF and Helmsley Trust Form Research Initiative Cancer Research Heroes, Research Update Personalized Cancer Vaccines to Conquer Cancer Research Update Personalized cancer neoantigen vaccines show success in two small studies Announcement PICI Network Presenters at #KScelltherapy23 Our Impact 2022 Year in Review Announcement PICI Network Researchers to Present at #ASH22 Announcement PICI Network Researchers to Present at #SITC22 Announcement Dana-Farber and Gladstone Institutes Join PICI Network Announcement, Our Impact Parker Institute Researchers Featured at #CICON22